Literature DB >> 17632123

Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion.

Atsushi Kuno1, Stuart D Critz, Lin Cui, Victoriya Solodushko, Xi-Ming Yang, Thomas Krahn, Barbara Albrecht, Sebastian Philipp, Michael V Cohen, James M Downey.   

Abstract

Although protein kinase C (PKC) plays a key role in ischemic preconditioning (IPC), the actual mechanism of that protection is unknown. We recently found that protection from IPC requires activation of adenosine receptors during early reperfusion. We, therefore, hypothesized that PKC might act to increase the heart's sensitivity to adenosine. IPC limited infarct size in isolated rabbit hearts subjected to 30-min regional ischemia/2-h reperfusion and IPC's protection was blocked by the PKC inhibitor chelerythrine given during early reperfusion revealing involvement of PKC at reperfusion. Similarly chelerythrine infused in the early reperfusion period blocked the increased phosphorylation of the protective kinases Akt and ERK1/2 observed after IPC. Infusing phorbol 12-myristate 13-acetate (PMA), a PKC activator, during early reperfusion mimicked IPC's protection. As expected, the protection triggered by PMA at reperfusion was blocked by chelerythrine, but surprisingly it was also blocked by MRS1754, an adenosine A(2b) receptor-selective antagonist, suggesting that PKC was somehow facilitating signaling from the A(2b) receptors. NECA [5'-(N-ethylcarboxamido) adenosine], a potent but not selective A(2b) receptor agonist, increased phosphorylation of Akt and ERK1/2 in a dose-dependent manner. Pretreating hearts with PMA or brief preconditioning ischemia had no effect on phosphorylation of Akt or ERK1/2 per se but markedly lowered the threshold for NECA to induce their phosphorylation. BAY 60-6583, a highly selective A(2b) agonist, also caused phosphorylation of ERK1/2 and Akt. MRS1754 prevented phosphorylation induced by BAY 60-6583. BAY 60-6583 limited infarct size when given to ischemic hearts at reperfusion. These results suggest that activation of cardiac A(2b) receptors at reperfusion is protective, but because of the very low affinity of the receptors endogenous cardiac adenosine is unable to trigger their signaling. We propose that the key protective event in IPC occurs when PKC increases the heart's sensitivity to adenosine so that endogenous adenosine can activate A(2b)-dependent signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17632123      PMCID: PMC2729547          DOI: 10.1016/j.yjmcc.2007.05.016

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  32 in total

1.  Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2.

Authors:  G Schulte; B B Fredholm
Journal:  Mol Pharmacol       Date:  2000-09       Impact factor: 4.436

2.  Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt.

Authors:  Nataliya V Solenkova; Viktoriya Solodushko; Michael V Cohen; James M Downey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-09-09       Impact factor: 4.733

3.  Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade.

Authors:  Sebastian Philipp; Xi-Ming Yang; Lin Cui; Amanda M Davis; James M Downey; Michael V Cohen
Journal:  Cardiovasc Res       Date:  2006-02-23       Impact factor: 10.787

4.  Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium.

Authors:  David K Glover; Laurent M Riou; Mirta Ruiz; Gail W Sullivan; Joel Linden; Jayson M Rieger; Timothy L Macdonald; Denny D Watson; George A Beller
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-12-09       Impact factor: 4.733

5.  The A2B adenosine receptor protects against inflammation and excessive vascular adhesion.

Authors:  Dan Yang; Ying Zhang; Hao G Nguyen; Milka Koupenova; Anil K Chauhan; Maria Makitalo; Matthew R Jones; Cynthia St Hilaire; David C Seldin; Paul Toselli; Edward Lamperti; Barbara M Schreiber; Haralambos Gavras; Denisa D Wagner; Katya Ravid
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

6.  Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors.

Authors:  Tobias Eckle; Thomas Krahn; Almut Grenz; David Köhler; Michel Mittelbronn; Catherine Ledent; Marlene A Jacobson; Hartmut Osswald; Linda F Thompson; Klaus Unertl; Holger K Eltzschig
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

7.  Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine.

Authors:  Hajime Kin; Amanda J Zatta; Mark T Lofye; Bradley S Amerson; Michael E Halkos; Faraz Kerendi; Zhi-Qing Zhao; Robert A Guyton; John P Headrick; Jakob Vinten-Johansen
Journal:  Cardiovasc Res       Date:  2005-04-01       Impact factor: 10.787

8.  Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo.

Authors:  Koichi Inagaki; Leon Chen; Fumiaki Ikeno; Felix H Lee; Ken-ichi Imahashi; Donna M Bouley; Mehrdad Rezaee; Paul G Yock; Elizabeth Murphy; Daria Mochly-Rosen
Journal:  Circulation       Date:  2003-11-03       Impact factor: 29.690

9.  Ischemic preconditioning protects by activating prosurvival kinases at reperfusion.

Authors:  Derek J Hausenloy; A Tsang; Mihaela M Mocanu; Derek M Yellon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-09-09       Impact factor: 4.733

10.  Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors.

Authors:  Y C Kim; X Ji; N Melman; J Linden; K A Jacobson
Journal:  J Med Chem       Date:  2000-03-23       Impact factor: 8.039

View more
  48 in total

1.  Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury.

Authors:  Ming Cai; Zachary M Huttinger; Heng He; Weizhi Zhang; Feng Li; Lauren A Goodman; Debra G Wheeler; Lawrence J Druhan; Jay L Zweier; Karen M Dwyer; Guanglong He; Anthony J F d'Apice; Simon C Robson; Peter J Cowan; Richard J Gumina
Journal:  J Mol Cell Cardiol       Date:  2011-09-12       Impact factor: 5.000

2.  A(2b) adenosine receptors can change their spots.

Authors:  Michael V Cohen; Xiulan Yang; James M Downey
Journal:  Br J Pharmacol       Date:  2010-04       Impact factor: 8.739

Review 3.  Mechanism of cardioprotection by early ischemic preconditioning.

Authors:  Xiulan Yang; Michael V Cohen; James M Downey
Journal:  Cardiovasc Drugs Ther       Date:  2010-06       Impact factor: 3.727

Review 4.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

5.  Modulation of receptor sensitivity: possible therapeutic target?

Authors:  Michel V Cohen; James M Downey
Journal:  Br J Pharmacol       Date:  2009-03       Impact factor: 8.739

Review 6.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

7.  Redox signaling at reperfusion is required for protection from ischemic preconditioning but not from a direct PKC activator.

Authors:  Yanping Liu; Xi-Ming Yang; Efstathios K Iliodromitis; Dimitrios T Kremastinos; Turhan Dost; Michael V Cohen; James M Downey
Journal:  Basic Res Cardiol       Date:  2007-11-12       Impact factor: 17.165

8.  Infarct limitation by a protein kinase G activator at reperfusion in rabbit hearts is dependent on sensitizing the heart to A2b agonists by protein kinase C.

Authors:  Atsushi Kuno; Nataliya V Solenkova; Victoriya Solodushko; Turhan Dost; Yanping Liu; Xi-Ming Yang; Michael V Cohen; James M Downey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-25       Impact factor: 4.733

9.  Hypoxia-regulated activity of PKCepsilon in the lens.

Authors:  Vladimir Akoyev; Satyabrata Das; Snehalata Jena; Laura Grauer; Dolores J Takemoto
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-11-07       Impact factor: 4.799

10.  Recent improvements in the development of A(2B) adenosine receptor agonists.

Authors:  Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Francesca Fruttarolo; Romeo Romagnoli; Delia Preti
Journal:  Purinergic Signal       Date:  2009-01-31       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.